Solid-State Strategy as a Development Discipline

For decades, solid-state chemistry has been recognized as a critical determinant of pharmaceutical performance and quality, yet solid-state decisions continue to be routinely deferred in early development. The solid state of an API encompasses its physical and molecular arrangement, including polymorphs, salts, hydrates, solvates, amorphous forms and cocrystals,^1–5 each presenting unique challenges. These attributes exert direct influence on the solubility, stability, bioavailability, processability and ultimately, the feasibility of the API’s clinical and commercial manufacture.^6–8

The deferral is not typically the result of ignorance of the importance of solid-state chemistry but rather reflects a set of rational pressures during the transition from discovery into development. Early programs are often constrained by limited material, compressed timelines, and a drive to generate toxicology and first-in-human material as quickly as possible. In that context, solid-state optimization is often treated as something that can be “cleaned up later” rather than as a form of early intervention in development architecture.

Several familiar assumptions tend to reinforce this mindset: “We just need enough material for tox.” “We’ll revisit solid form selection after phase 1.” “Intellectual property can be filed around the form we have.” Each of these positions feels reasonable in isolation. Early development rewards speed, and solid-state work is often perceived as merely an incremental optimization rather than a real, gating decision. As a result, teams often advance the first workable form that supports near-term needs with the assumption that there will be sufficient flexibility downstream for optimization.

The critical misunderstanding is not with solid-state science itself, but the optimal timing of solid-state decisions. What can appear in early development to be a reversible technical choice, may become a structural constraint once clinical materials are qualified, regulatory filings are made, and patent strategies crystallize around a specific form.

The Hidden Cost Curve of Decision Deferral

The consequences of deferring solid-state decisions accumulate along a cost curve that steepens as development progresses.

Early in development, solid-form changes are comparatively inexpensive. Screening additional polymorphs or salts typically requires limited material and modest effort. At this stage, solid-state flexibility remains high, and alternative forms can be evaluated without disrupting program timelines.

That flexibility narrows as development advances. Once a form has been used to generate toxicology or early clinical material, additional constraints emerge. Metastable polymorphs, for example, may convert to more stable forms during processing or storage, introducing variability in dissolution, stability or bioavailability.⁷ Manufacturing processes become tuned to specific solid-state attributes, magnifying the effort required to accommodate change. Regulatory documentation also begins to reflect assumptions about the selected form and its control strategy.^9–11

Beyond this inflection point, changing solid form becomes expensive, potentially requiring reformulation, revalidation and bridging studies. Comparability arguments grow more complex, while patent strategies built around a particular form may need to be revisited or expanded under less favorable conditions. The literature contains well-documented examples where unanticipated solid-state behavior emerged late, forcing production halts and extensive remediation efforts.² These cautionary cases illustrate a broader pattern: once solid-state choices intersect with late-stage manufacturing, regulatory review, and commercial supply, the freedom to act has largely disappeared.

Beyond this inflection point, solid-state decisions move from being important to being inevitable. The question is no longer whether solid-state risk will surface but when it will surface and whether teams will have the ability to respond when it does.

Solid-State Decision Branches

Solid-state chemistry offers multiple pathways for shaping API performance, and each pathway carries distinct implications for development flexibility.

Polymorphs represent different crystalline arrangements of the same molecular entity that may differ in stability, solubility, process behavior, and bioavailability.^3,4 Salts introduce counterions that can significantly alter solubility, hygroscopicity, and manufacturability, particularly for poorly soluble compounds.^5,9 Amorphous forms may enhance dissolution but raise stability and control challenges. Cocrystals and solvates offer additional avenues for tuning properties, while introducing their own regulatory and IP considerations.^12–16

These options are frequently presented as a catalog of techniques, but in practice, they function as decision branches. Each choice influences not only physicochemical performance but downstream manufacturability, regulatory strategy and IP optionality. Critically, these branches are not all available indefinitely, and as development advances, some paths close while others become entrenched.

Understanding the solid-state landscape means recognizing which decisions preserve flexibility and which quietly foreclose it. Below, we examine when those paths close and how sponsors can account for that timing in their decision-making.

From Screening Techniques to Decision Logic

Solid-state screening is often described in technical terms: polymorph screens, salt selection matrices, high-throughput crystallization experiments, and automated characterization platforms.^13–15 These tools are well established and increasingly efficient, but optimal timing is less understood.

In practice, solid-state screening is rarely delayed because teams doubt its value, but since early development rewards forward motion, screening is perceived as exploratory work that can be postponed without significant consequences. As a result, solid-state tools are often applied reactively, after a form has already been selected to meet early needs.

However, choosing to avoid early screening is, itself, a decision. Advancing a single workable form without systematically understanding the surrounding solid-state landscape effectively closes the door to alternatives that may have been the key to the program’s success.

Sequencing Matters

Understanding the polymorphic landscape of an API is foundational. Polymorph screening establishes what crystalline forms exist, how stable they are relative to one another, and how they respond to changes in processing, temperature, and humidity.^3,4 This understanding defines the baseline risks and opportunities associated with any subsequent development path.

Salt selection is most effective when undertaken after polymorphic behavior is understood. Salts can dramatically improve solubility, processability, or stability,⁵ but they also introduce additional regulatory, manufacturing, and IP considerations. When salt selection is pursued as a default first step rather than a strategic extension informed by polymorphic control, it can lock programs into paths that are difficult to revisit later.

High-throughput and automated screening platforms make it technically feasible to explore these options early.^13–15 The limiting factor is rarely capability but timing and prioritization. The central question, therefore, is not how to screen solid forms, but when screening preserves choice versus when it simply validates decisions already made.

How Solid-State Decisions Actually Get Made (and Why They Fail)

Most solid-state decisions are not made in formal decision meetings but emerge incrementally under the competing pressures that characterize early development. Common internal debates recur across programs reflecting real constraints, such as limited API availability, compressed timelines, finite budgets, and uncertainty about clinical success. Early development teams are incentivized to minimize upfront cost and maximize speed to key inflection points.

However, a failure mode can result when these short-term optimizations are mistakenly viewed as reversible choices. Once a form is embedded in toxicology studies, clinical supply chains, regulatory filings, and patent strategies, the organizational cost of revisiting it increases significantly. At that point, even clearly suboptimal solid-state behavior may need to be tolerated simply because change is too disruptive. Importantly, this is not a failure of scientific judgment; it is a failure of decision framing.

Solid-State Strategy as IP Optionality

Solid-state decisions influence intellectual property strategy in ways that are often underappreciated early in development. Under U.S. patent law, solid forms, including polymorphs, salts, and related derivatives, may be patentable if they meet criteria of novelty and non-obviousness.¹⁷ Secondary solid-form patents are commonly used as part of broader life cycle management strategies and are reflected in regulatory listings, such as the FDA Orange Book.^18–20

The strategic significance lies not in any guarantee of exclusivity but in optionality. Early understanding of the solid-state landscape can open the door for developers to pursue multiple IP positions over time. In contrast, advancing a single form without exploring alternatives can limit future filings or force reliance on narrower claims.

Viewed appropriately, solid-state work is not merely a matter of protecting against failure but a means of preserving strategic degrees of freedom as programs mature and commercial stakes increase.

Tools for Life Cycle Management

Beyond initial development, solid-state innovation has value in extending and differentiating pharmaceutical products. Strategies involving alternative salts, polymorphs, and formulations have been used to address bioavailability limitations and improve manufacturability, including changes in salt form or crystalline structure for dabigatran, buspirone, and chloramphenicol palmitate.^21–23

These cases illustrate how solid-state choices support life cycle management. They also underscore an important limitation: to keep these opportunities accessible, solid-state flexibility must be preserved earlier. When programs enter late development with a narrow or poorly characterized solid-state foundation, these life cycle options are more constrained and typically more expensive to pursue. Solid-state strategy is best understood not as a late-stage rescue tool but as an early investment that enables future maneuverability.

Timing is the Strategic Variable

Solid-state chemistry has never been optional in drug development. What is often misunderstood is when solid-state decisions cease to be flexible.

Across development programs, the cost of solid-state work is frequently framed as an upfront investment decision. In practice, however, greater cost is rarely incurred by doing the work early but rather by doing it after clinical commitments, regulatory filings, and IP strategies have narrowed the available paths ahead.

By the time solid-state risk becomes visible at scale, many of the most consequential and often irreversible choices have already been made. Manufacturing processes have been tuned to a specific form. Regulatory narratives have solidified. Patent strategies have crystallized around assumptions that are difficult to revisit. At that stage, even well-understood solid-state problems can be expensive, disruptive, impractical, or even impossible to correct.

The implication for sponsors is not that every program requires exhaustive solid-state optimization from the outset. Rather, it is that solid-state decisions should be treated as development architecture and candidates for early intervention: made deliberately, sequenced appropriately, and aligned with the points at which flexibility quietly collapses.

Inevitably, solid-state challenges will arise. The question is whether they arise while teams still have the freedom to act. Programs that recognize this timing dynamic preserve optionality across manufacturing, regulatory strategy, and life cycle planning. Those that do not often discover that the apparent speed gained early is offset by constraints that emerge later, when change carries its highest cost.

References

1. Stahly GP. Diversity in single- and multiple-component crystals: the search for and prevalence of polymorphs and cocrystals. Crystal Growth & Design. 2007;7:1007-1026.
2. Bauer J, Spanton S, Henry R, et al. Ritonavir: an extraordinary example of conformational polymorphism. Pharmaceutical Research. 2001;18:859-866.
3. Brittain HG. Polymorphism in Pharmaceutical Solids. 2nd ed. New York, NY: Informa Healthcare; 2009.
4. Bernstein J. Polymorphism in Molecular Crystals. Oxford, UK: Oxford University Press; 2002.
5. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research. 1995;12:413-420.
6. Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. Journal of the American Chemical Society. 1897;19:930-934.
7. Raw AS, Yu LX. Pharmaceutical solid polymorphism in abbreviated new drug application (ANDA) review. Advanced Drug Delivery Reviews. 2004;56:235-236.
8. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. Journal of Pharmacological and Toxicological Methods. 2000;44:235-249.
9. Yu LX, Amidon G, Khan MA, et al. Understanding pharmaceutical quality by design. AAPS Journal. 2014;16:771-783.
10. Byrn SR, Pfeiffer R, Ganey M, Hoiberg C, Poochikian G. Pharmaceutical solids: a strategic approach to regulatory considerations. Pharmaceutical Research. 1995;12:945-954.
11. Chemburkar SR, Bauer J, Deming K, et al. Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. Organic Process Research & Development. 2000;4:413-414.
12. Morissette SL, Almarsson Ö, Peterson ML, et al. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Advanced Drug Delivery Reviews. 2004;56:275-300.
13. Allesø M, Tian F, Cornett C, Rantanen J. Towards effective solid form screening. Journal of Pharmaceutical Sciences. 2010;99:3711-3718.
14. Giron D. Investigations of polymorphism and pseudo-polymorphism in pharmaceuticals by combined thermoanalytical techniques. Journal of Thermal Analysis and Calorimetry. 2001;64:37-60.
15. Aaltonen J, Allesø M, Mirza S, Lubomirska V, Abildskov J, Rantanen J. Solid form screening: a review. European Journal of Pharmaceutics and Biopharmaceutics. 2009;71:23-37.
16. Paulekuhn GS, Dressman JB, Saal C. Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database. Journal of Medicinal Chemistry. 2007;50:6665-6672.
17. United States Code. 35 U.S.C. §§102-103.
18. US Food and Drug Administration. Approved Drug Products With Therapeutic Equivalence Evaluations (Orange Book).
19. Hemphill CS, Sampat BN. Evergreening, patent challenges, and effective market life in pharmaceuticals. Journal of Health Economics. 2012;31:327-339.
20. Newman AW, Brittain HG. Principles and applications of solid-state chemistry in pharmaceutical science. Annual Reports in Medicinal Chemistry. 1995;30:243-252.
21. Vogt, F. G., & Williams, G. R. (2010). Advanced approaches to effective solid-state analysis: X-ray diffraction, vibrational spectroscopy and solid-state NMR. American Pharmaceutical Review, 13(7), 58–65.
22. Nerurkar J, Beach L, Park C, Wurster DE, Singh P. Buspirone hydrochloride polymorphism: stability, solubility, flow properties, and compression behavior. AAPS PharmSciTech. 2023;24:219.
23. Aguiar AJ, Krc J, Kinkel AW, Samyn JC. Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate. Journal of Pharmaceutical Sciences. 1967;56:847-853.